多拉司瓊

用途

• Anti-emetic, particularly for patients receiving chemotherapeutics
• Vomiting disorders
• Prevent vomiting
• Treat vomiting
• General anti-emetic
• Anti-emetic, particularly for patients receiving chemotherapeutics
• General anti-emetic
• Vomiting disorders
• Prevent vomiting
• Treat vomiting

給藥方式

可能的副作用

• Dose-related ECG interval prolongation (PR, QTc, JT prolongation, and QRS widening)
• Headache (reported in humans)
• Dizziness (reported in humans)

注意事項與禁忌

• Known hypersensitivity to dolasetron
• Atrioventricular (AV) block II to III
• Markedly prolonged QTc interval
• Use with extreme caution in patients susceptible to cardiac conduction interval prolongation. This includes patients with hypokalemia, hypomagnesemia, congenital QT syndrome, those receiving anti-arrhythmic drugs or diuretics that induce electrolyte abnormalities, or those who have received a cumulative high dose of anthracycline chemotherapy. Note that 5-HT3 antagonists are generally ineffective for vomiting associated with feline hepatic lipidosis or mechanical GI obstruction.

藥物相互作用

• Atenolol: May reduce the clearance and increase blood levels of hydrodolasetron
• Cimetidine: May reduce the clearance and increase blood levels of hydrodolasetron
• Ketoconazole: May reduce the clearance and increase blood levels of hydrodolasetron
• Phenobarbital: Can reduce hydrodolasetron blood levels
• Rifampin: Can reduce hydrodolasetron blood levels

常見問題